Question · asked by 1 review
Zuclopenthixol dihydrochloride vs placebo: Adverse effects ‐ important extrapyramidal adverse effects
- Population
- patients with schizophrenia
- Intervention
- Zuclopenthixol dihydrochloride
- Comparison
- placebo
- Outcome
- Adverse effects ‐ important extrapyramidal adverse effects
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect… compared with placebo (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Zuclopenthixol dihydrochloride vs placebo Adverse effects: Clinically important general adverse effect (extrapyramidal effects ‐ UKU side effect rating scale) · people with schizophrenia It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect… compared with placebo (very low certainty). Zuclopenthixol dihydrochloride for schizophrenia (2017) · Cochrane Headline outcomes only | RR 6.07 [0.86, 43.04] | 1 study · 28 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.